Table 1.
Baseline characteristics.
| Characteristic | n = 752 |
|---|---|
| Age, median years (IQR) | 37 (33–43) |
| Gender, n (%) | |
| Male | 570 (75.8) |
| Female | 182 (24.2) |
| Mode of transmission, n (%) | |
| Injection drug use | 454 (60.4) |
| Heterosexual contact | 265 (35.2) |
| Male-to-male sex | 17 (2.3) |
| Blood recipient | 6 (0.8) |
| Other/not identified | 10 (1.3) |
| CD4 cell count, median cells/mm3 (IQR) | 141 (76–208) |
| HIV RNA load, median log10 copies/ml (IQR) | 5.4 (4.8–5.8) |
| AIDS defining illness, n (%) | 446 (59.3) |
| Malignancy, n (%) | 22 (2.9) |
| Liver related diseases, n (%) | |
| Anti-HCV+ | 397 (52.8) |
| HbsAg+ | 63 (8.4) |
| Anti-HCV+/HbsAg+ | 47 (6.3) |
| Cirrhosis | 104 (13.8) |
| Initial HAART regimen, n (%) | |
| AZT + 3TC + EFV | 310 (41.2) |
| AZT + 3TC + NVP | 86 (11.4) |
| AZT + 3TC + LPV/r | 3 (0.4) |
| ABC + 3TC + EFV | 187 (24.9) |
| ABC + 3TC + NVP | 15 (2.0) |
| ABC + 3TC + LPV/r | 2 (0.3) |
| TDF + FTC + EFV | 9 (1.2) |
| TDF + FTC + NVP | 2 (0.3) |
| d4T + 3TC + EFV | 126 (16.7) |
| d4T + 3TC + NVP | 12 (1.6) |